^
    1year
    Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas. (PubMed, Cell Biosci)
    FGFR2 oncogenic alterations have different clinicopathological features and respond differently to SMKIs.
    Journal
    |
    TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    TP53 mutation • FGFR2 mutation • FGFR2 fusion • FGFR2 translocation
    1year
    Calcified chondroid mesenchymal neoplasm with an FN1-FGFR2 translocation, intralesional fat, diffuse CD34-positivity, and a lack of giant cells: A case report with uncommon findings (ASDP 2023)
    The findings in this presented case help continue to expand the knowledge of an emerging subcutaneous pathologic entity, and highlight some uncommon features that should not dissuade one from making a diagnosis of CCMN. Poster type: Poster Defense
    Clinical
    |
    FGFR2 (Fibroblast growth factor receptor 2) • CD34 (CD34 molecule) • FN1 (Fibronectin 1)
    |
    CD34 positive • FGFR2 translocation
    over1year
    A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients. (PubMed, Diagnostics (Basel))
    FISH results were correlated with that of NGS on some samples. Biallelic translocations and a novel FGFR2 translocation involving the partner gene, SHROOM3, t(4;10) (q21;q26), were identified in a local iCCA patient.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion • FGFR fusion • FGFR2 translocation
    over1year
    Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features. (PubMed, Expert Rev Mol Diagn)
    Furthermore, positive FGFR2 rearrangement occurred only in small duct type ICC and IDH1/2 was mutated mainly in small duct type ICC. The subclassification system was applicable and the ICC subtypes had distinct clinicopathological characteristics, prognostic outcome, and IDH1/2 mutation pattern.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    KRAS mutation • FGFR2 mutation • FGFR2 rearrangement • FGFR2 translocation
    2years
    Functional Investigation of the Tumoural Heterogeneity of Intrahepatic Cholangiocarcinoma by In Vivo PET-CT Navigation: A Proof-of-Concept Study. (PubMed, J Clin Med)
    Tumour heterogeneity at PET-CT may drive biopsy to sample the most informative ICC areas. Even more relevant, these preliminary data show the possibility of achieving a non-invasive evaluation of IH in ICC, paving the way for an imaging-based precision-medicine approach.
    Preclinical • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 translocation
    over2years
    Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) (clinicaltrials.gov)
    P2, N=147, Completed, Incyte Corporation | Trial completion date: Sep 2021 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
    Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)
    almost3years
    HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=141, Not yet recruiting, Hutchison Medipharma Limited
    New P1/2 trial • Combination therapy • IO biomarker
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • HMPL-453
    3years
    Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) (clinicaltrials.gov)
    P2, N=147, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)
    over3years
    Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) (clinicaltrials.gov)
    P2, N=147, Active, not recruiting, Incyte Corporation | Trial primary completion date: Jun 2019 --> Sep 2021
    Clinical • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)
    over3years
    Clinical Study of ICP-192 in Solid Tumors Patients (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Trial completion date: Jun 2021 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 fusion • FGFR2 translocation
    |
    gunagratinib (ICP-192)
    over3years
    [VIRTUAL] Matching Adjusted Indirect Treatment Comparison of FGFR2+ Patients in the FIGHT-202 Trial vs. Patients with Unspecified FGFR2 Status Receiving Standard of Care Treatments (ISPOR 2021)
    CONCLUSIONS : Based on the available evidence and on the MAIC, patients treated with pemigatinib are expected to experience longer time in remission and survival than cholangiocarcinoma patients treated according to SoC. The robustness and interpretation of the MAIC results is subject to known methodological limitations, including the unknown FGFR2 status of and impact on patients recruited in the available comparator studies.
    Clinical
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)
    almost4years
    Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas. (PubMed, Cell Death Dis)
    Furthermore, the kinase-deficient mutant of the sub-classical fusion also lost its sensitivity to the FGFR-specific inhibitors. Taken together, our study suggests that it is essential to determine the breakpoint and type of FGFR2 fusions in the small bile duct subtype of ICC for the targeted treatment.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion • FGFR fusion • FGFR2 translocation
    almost4years
    Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) (clinicaltrials.gov)
    P2, N=147, Active, not recruiting, Incyte Corporation | Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)
    over4years
    Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) (clinicaltrials.gov)
    P2, N=147, Active, not recruiting, Incyte Corporation | Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Nov 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)
    5years
    Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) (clinicaltrials.gov)
    P2, N=147, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Jun 2020
    Clinical • Enrollment closed • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 translocation
    |
    Pemazyre (pemigatinib)